Ranbaxy Laboratories Ltd. Q4 CY11 net loss stood at Rs 29.83bn vs a net loss of Rs 975mn in the same period last year.
The provision for USFDA settlement stood at Rs 26.48bn.
Forex loss stood at Rs 8.38bn vs a gain of Rs 1.32bn.
EBIDTA stood at Rs 8.60bn vs Rs 2.30bn YoY; EBIDTA margin stood at 22.7% vs 10.8% YoY.
Ranbaxy Laboratories re-appoints Arun Sawhney as CEO and MD
ABB Q4 net profit at Rs641.126 mn